Construction of a DNA vaccine based on the Mycobacterium tuberculosis Ag85A/MPT64 fusion gene and evaluation of its immunogenicity

Kaufmann SH: Is the development of a new tuberculosis vaccine possible? Nat Med. 6:955–960. 2000. View Article : Google Scholar : PubMed/NCBI

Fuller DH, Rajakumar PA, Wilson LA, et al: Introduction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol. 76:3309–3317. 2002. View Article : Google Scholar : PubMed/NCBI

Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K and Ellner JJ: Human immune response to Mycobacterium tuberculosis antigens. Infect Immun. 59:665–670. 1991.

Weldingh K, Rosenkrands I, Jacobsen S, Rasmussen PB, Elhay MJ and Andersen P: Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun. 66:3492–3500. 1998.PubMed/NCBI

Malin AS, Huygen K, Content J, et al: Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect. 2:1677–1685. 2000.

Romano M, Roupie V, Wang XM, et al: Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology. 118:321–332. 2006. View Article : Google Scholar : PubMed/NCBI

Oettinger T, Holm A and Hasløv K: Characterization of the delayed type hypersensitivity-inducing epitope of MPT64 from Mycobacterium tuberculosis. Scand J Immunol. 45:499–503. 1997. View Article : Google Scholar : PubMed/NCBI

Kamath AT, Feng CG, Macdonald M, Briscoe H and Britton WJ: Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun. 67:1702–1707. 1999.PubMed/NCBI

Tehranchian S, Akbarzadeh T, Fazeli MR, Jamalifar H and Shafiee A: Synthesis and antibacterial activity of 1-[1,2,4-triazol-3-yl] and 1-[1,3,4-thiadiazol-2-yl]-3-methylthio-6,7-dihydrobenzo[c]thiophen-4(5h)ones. Bioorg Med Chem Lett. 15:1023–1025. 2005.

Wang Z, Potter BM, Gray AM, Sacksteder KA, Geisbrecht BV and Laity JH: The solution structure of antigen MPT64 from Mycobacterium tuberculosis defines a new family of beta-grasp proteins. J Mol Biol. 366:375–381. 2007.PubMed/NCBI

Bastos RG, Ueti MW, Knowles DP and Scoles GA: The Rhipicephalus (Boophilus) microplus Bm86 gene plays a critical role in the fitness of ticks fed on cattle during acute Babesia bovis infection. Parasit Vectors. 3:1112010. View Article : Google Scholar : PubMed/NCBI

Choi SS, Chung E and Jung YJ: Newly identified CpG ODNS, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity. J Microbiol. 48:512–517. 2010. View Article : Google Scholar : PubMed/NCBI

de Klerk LM, Michel AL, Bengis RG, Kriek NP and Godfroid J: BCG vaccination failed to protect yearling African buffaloes (Syncerus caffer) against experimental intratonsilar challenge with Mycobacterium bovis. Vet Immunol Immunopathol. 137:84–92. 2010.PubMed/NCBI

Liang Y, Wu X, Zhang J, et al: The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. Vaccine. 26:4536–4540. 2008. View Article : Google Scholar : PubMed/NCBI

Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K and Weiner DB: DNA vaccines for targeting bacterial infections. Expert Rev Vaccines. 9:747–763. 2010. View Article : Google Scholar : PubMed/NCBI

Cai H, Tian X, Hu XD, Zhuang YH and Zhu YX: Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis. DNA Cell Biol. 23:450–456. 2004. View Article : Google Scholar : PubMed/NCBI

Takeno M, Murakami S and Ishigatsubo Y: Tuberculosis associated with anti-TNF therapy. Nippon Rinsho. 65:1308–1313. 2007.(In Japanese).